Trial reportScientific reports2020
The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial.
Trial report in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials.BMC nephrology · 2025Pooled it
- Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis.PloS one · 2022Pooled it
- Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.Health technology assessment (Winchester, England) · 2025Trial
- Aldosterone excess, blood pressure control, and kidney outcomes in chronic kidney disease: findings from the Cardiovascular and Metabolic Disease Etiology Research Center-High Risk (CMERC-HI) Study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.Kidney international reports · 2026Article
- DPA/AA ratio as a potential biomarker of primary aldosteronism in young and middle-aged adults.Frontiers in endocrinology · 2026Article
- Risk of Hypertension and Chronic Kidney Disease Following Aldosterone Dysregulation.American journal of hypertension · 2026Article
- Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD.Renal failure · 2025Article
- Article
- Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.Clinical journal of the American Society of Nephrology : CJASN · 2024Review
- Older patients are less prone to fast decline of renal function: a propensity-matched study.International urology and nephrology · 2023Article
- Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II.International journal of molecular sciences · 2023Article
- Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis.International journal of hypertension · 2023Article
- Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.Frontiers in endocrinology · 2023Review
- A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics.International journal of molecular sciences · 2022Review
- [Inhibition of the renin-angiotensin-aldosterone system].Der nephrologe · 2022Review
- Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease.International journal of molecular sciences · 2021Review
- Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Involvement of Tricarboxylic Acid Cycle Metabolites in Kidney Diseases.Biomolecules · 2021Review
- Renal Injuries in Primary Aldosteronism: Quantitative Histopathological Analysis of 19 Patients With Primary Adosteronism.Hypertension (Dallas, Tex. : 1979) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progression of chronic kidney disease (CKD) cannot be completely inhibited. We first explored factors contributing to CKD progression in patients with CKD in a prospective observational study. In the next phase, we focused on the effects of aldosterone, conducting a single-blinded placebo-controlled study using the selective mineralocorticoid receptor antagonist (MRA), eplerenone (25 mg/day). We recruited patients with CKD stage 2 and 3 whose plasma aldosterone concentration was above 15 ng/dL based on the prior data of a prospective observational study. In the CKD cohort study (n = 141), baseline plasma aldosterone concentration was identified as an independent contributory factor for the future rate of change in estimated glomerular filtration rate (eGFR). When the cut-off value for aldosterone was set at 14.5 ng/dL, the decline rate was significantly higher in patients with higher plasma aldosterone concentration (- 1.22 ± 0.39 ml/min/1.73 m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.